bpc-157 regulatory status fda not approved BPC-157: The Real Reason Why It's Regulatory Updates on Compounded Peptides
Description
Drowsiness after injection is normal and expected
Unwanted tissue growth or fibrosis is a legitimate concern when uncoupled to growth peptides are improperly used
Other peptide protocols may be shorter term
The peptide's long-term safety profile in humans remains unknown
Research demonstrates up to 70% increases in type I collagen production in dermal fibroblasts at optimal concentrations
Needlestick injuries can transmit infections and pose significant health risks to others
